Streetbeat News

SXTP

60 Degrees Pharmaceuticals, Inc.

Industry

Biotechnology

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

Open

1.63

Mkt cap

3.2M

Volume

289K

High

1.65

P/E Ratio

-0.15

52-wk high

18.36

Low

1.35

Div yield

N/A

52-wk low

0.70

Sixty Degrees Pharmaceuticals and Tufts Medical Center have entered a patent license agreement to develop tafenoquine for the treatment and prevention of babesiosis. They aim to co-own patents and seek FDA approval to address unmet medical needs.

Portfolio Pulse from

December 23, 2024 | 2:15 pm

60 Degrees Pharmaceuticals is expanding its clinical trial for tafenoquine, a treatment for babesiosis, to Brigham and Women's Hospital. This trial addresses a critical unmet medical need.

Portfolio Pulse from

December 11, 2024 | 2:15 pm

60 Degrees Pharmaceuticals Inc. (SXTP) reported a Q3 loss of $0.93 per share, missing the Zacks Consensus Estimate of a $0.60 loss. This is an improvement from the $3.60 loss per share a year ago.

Portfolio Pulse from

November 14, 2024 | 9:45 pm

60 Degrees Pharmaceuticals (SXTP) reported a 164% revenue growth in its third quarter 2024 earnings, along with clinical progress on ARAKODA® for infectious diseases and babesiosis.

Portfolio Pulse from

November 14, 2024 | 7:45 pm

60 Degrees Pharmaceuticals shares rise as the company begins a nine-month promotional pilot for ARAKODA.